Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice

Hepatology

Volumn 46, Issue 2, 2007, Pages 414-423

  García Ruiz, Inmaculada ^a   Rodríguez Juan, Cristina ^a   Díaz Sanjuán, Teresa ^a   Martínez, Miguel Ángel ^a   Muñoz Yagüe, Teresa ^a   Solís Herruzo, José A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; FATTY ACID; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ELECTRON MICROSCOPY; FATTY ACID OXIDATION; FATTY LIVER; HISTOLOGY; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER DISEASE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; FATTY LIVER; LIPID PEROXIDATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MICROSCOPY, ELECTRON; MITOCHONDRIA, LIVER; PPAR GAMMA; THIAZOLIDINEDIONES; TYROSINE;

EID: 34548319082     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21687     Document Type: Article

References (49)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparal N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
2. McCullough AJ. The epidemiology and risk factors of NASH. In Farrell GC, George J, de la M. Hall P, and McCullough AJ, eds. Fatty liver disease. NASH and related disorders. Malden, Blackwell, 2005:23-37.
3. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002;35:373-379.
4. Sanyal AJ. The pathogenesis of NASH: human studies. In Farrell GC, George J, de la M. Hall P, and McCullough AJ, eds. Fatty liver disease. NASH and related disorders. Malden, Blackwell, 2005:76-90.
5. Solis-Herruzo JA, García-Ruiz I, Pérez-Carreras M, Muñoz-Yagüe MT. Non-alcoholic liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 2006;98:817-827.
6. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidine dione es a high affinity ligand for peroxisoma proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-12956.
7. Jarvinen HY. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
8. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nornalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
9. Newschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
10. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004;39:188-198.
11. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Manderino LJ, DeFronzo RA. Effects of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001;44:2210-2219.
12. Sutter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM patients. Diabetic Care 1992;15:193-203.
13. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001;10:537-547.
14. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant M, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115.
15. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89-104.
16. Farrell GC. Animal models of steatohepatitis. In Farrell GC, George J, de la M. Hall P, and McCullough AJ, eds. Fatty liver disease. NASH and related disorders. Malden, Blackwell, 2005;91-108.
17. Kleiner DE, Brunt EM, van Natta M, Behling C, Contos MJ, Cummings OW, et al. Desingn and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005;41:1313-1321.
18. Sánchez-Alcázar JA, Schneider E, Martínez MA, Carmona P, Hernández-Munoz I, Siles E, et al. TNFα increases the steady-state reduction of cytochrome B of the mitochondrial respiratory chain in metabolically inhibited L929 Cells. J Biol Chem 2000;275:13353-13361.
19. García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. HEPATOLOGY 2006;44:581-591.
20. Crane DI, Kalish JE, Gould SJ. The Pichia Pastoris PAS4 gene encodes an ubiquitin-conjugating enzyme required for peroxisome assembly. J Biol Chem 1994;269:21835-21844.
21. Watkins PA, Ferrell EV, Jr, Pedersen JI, Hoefler G. Peroxisomal fatty acid β-oxidation in HepG2 Cells. Arch Biochem Biophys 1991;289:329-336.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
23. Eady JJ, Osta T, Dennis MF, Stratford MR, Peacock JH. Glutathione determination in the Tietze enzymatic recycling assay and its relationship to cellular radiation response. Br J Cancer 1995;72:1089-1095.
24. Santiago B, Galindo M, Palao G, Pablos JL. Intracellular regulation of Fas-induced apoptosis in human fibroblasts by extracellular factors and cycloheximide. J Immunol 2004;172:560-566.
25. Turko IV, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol 2001;281:H2289-H2294.
26. Lang A, Schrum L, Schoonhoven R, Tuvia S, Solis-Herruzo JA, Tsukamoto H, et al. Expression of the small heat shock protein αb-crystallin is induced after hepatic stellate cells activation. Am J Physiol 2000;279:G1333-G1342.
27. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAγ mice exhibit increased hepatic PPARγ-1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001;35:17-23.
28. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J Lipid Res 2002;43:1809-1817.
29. Memon Ra, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α and PPAR-γ) messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000;141:4021-4031.
30. nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:30.
31. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetic Care 2002;25:815-821.
32. Menees SB, Anderson MA, Chensue SW, Moseley RH. Hepatic injury in a patients taking rosiglitazone. J Clin Gastroenterol 2005;39:638-640.
33. Nagasaka S, Abe T, Kawakami A, Kusaka I, Nakamura T, Ishikawa S, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabetes Med 2002;19:344-348.
34. Inoue I, Katayama S, Takahashi K, Negishi K, Mizayaki T, Sonoda M, et al. Troglitazone has a scavenging effect on reactive oxygen species. Bioch Biophys Res Commun 1997;235:116.
35. Narayanan PK, Hart T, Elcock F, Zhang C, Hahn L, McFarland D, et al. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry 2003;52A:28-35.
36. Young T, Cunningham CC, Bailey SM. Reactive oxygen species production by the mitochondrial respiratory chain in isolated rat hepatocytes and liver mitochondria: studies using myxothiazol. Arch Biochem Biophys 2002;405:65-72.
37. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003;38:999-1007.
38. Schönfeld P, Reiser G. Rotenone-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria. J Biol Chem 2006;281:7136-7142.
39. Shishido S, Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E, et al. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. HEPATOLOGY 2003;37:136-147.
40. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002;69:131-138.
41. Scatena R, Bottoni P, Martorana GE, Ferrari F, De Sole P, Rossi C, et al. Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Comm 2004;319:967-973.
42. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I. Diabetes 2004;53:1052-1059.
43. Gluck MR, Youngster SK, Ramsay RR, Singer TP, Nicklas WJ. Studies on the characterization of the inhibitory mechanism of 4 alkylated 1-methyl 4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles. J Neurochem 1994;63:655-661
44. Davidoff F. Effects of guanidine derivatives on mitochondrial function. III. The mechanism of phenylethylbiguanidine accumulation and its relationship to in vitro respiratory inhibition. J Biol Chem 1971;246:4017-4027
45. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibits inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003;37:343-350
46. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
47. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005;54:880-885.
48. Radi R, Cassina A, Hodara R. Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem 2002;383:401-409.
49. Marzella L, Trump BF. Pathology of the cell: ultrastructural features. In: Papadimitriou JM, Henderson DW, Spagnolo DV, eds. Diagnostic ultrastructure of non-neoplastic diseases. Edinburgh: Churchill Livingstone, 1992: 46.